Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
André DaherGhait AljayyoussiDhelio PereiraMarcus V G LacerdaMárcia A A AlexandreCristiana T NascimentoJúlio Castro AlvesLaís Bastos da FonsecaDiego Medeiros Dias da SilvaDouglas Pereira PintoDanielle Fonseca RodriguesAna Carolina Rios SilvinoTaís Nóbrega de SousaCristiana Ferreira Alves de BritoFeiko O Ter KuileDavid G LallooPublished in: Malaria journal (2019)
Genotyping of P. vivax showed that activation of related (homologous) hypnozoites was the most frequent cause of recurrence. The high proportion of the impaired CYP2D6 activity among patients with recurrent infections suggests that slow primaquine metabolism might influence related relapse rates in Brazil among patients receiving primaquine for radical cure, although confirmatory studies are needed. There was no association between drug exposure of the long-acting ACT component (schizonticidal drugs) and risk of related relapse. ACT was well tolerated. These results provide further re-assurance about the safety and efficacy of ACT when combined with short course primaquine to treat uncomplicated malaria vivax in Brazil. Trial registration RBR-79s56s ( http://www.ensaiosclinicos.gov.br/rg/RBR-79s56s/ ).